CellFree Sciences Co., Ltd. received support from Ehime Prefecture under the "Ehime Prefecture New Growth Manufacturing Company Comprehensive Support Program in FY2021".
We are grateful, that Ehime Prefecture selected an application by CellFree Sciences under their "Ehime Prefecture New Growth Manufacturing Company Comprehensive Support Program in FY2021".
Having access to a unique set of about 23,000 human full-length proteins, CellFree Sciences will apply their own technologies including a protein bead array platform to search for new drug targets and therapeutic concepts.
While about 10 to 15% of the human proteins could play a role in disease, presently only about 2% of the human proteins can be directly targeted by a drug. Hence, there is a clear need to expand the number of druggable proteins to develop new therapeutic concepts and to cover a wider range of disease. In this project, we will apply new concepts to target drug targets for proteolytic degradation utilizing E3 ligases. Having extensive knowledge on E3 ligases, it is hoped that utilizing E3 ligases will offer new leads allowing for targeted proteolysis of selected targets while having less side effects than other drug candidates.
Project period: July 5, 2021-February 28, 2022.
